HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

vitreous floaters

Also Known As:

eye floaters; myodesopsia

Networked: 100 relevant articles (19 outcomes, 9 trials/studies)

Relationship Network

Disease Context: Research Results

Nervous System Diseases: 14178
- Neurologic Manifestations: 7102
  - Sensation Disorders: 117
    - Vision Disorders: 2977
      - vitreous floaters: 100
Eye Diseases: 3522
- Vision Disorders: 2977
  - vitreous floaters: 100
Signs and Symptoms Pathological Conditions
- Signs and Symptoms
  - Neurologic Manifestations: 7102
    - Sensation Disorders: 117
      - Vision Disorders: 2977
        vitreous floaters: 100

Related Diseases

1.	Cataract (Cataracts)
2.	Dry Eye Syndromes (Dry Eye Syndrome)
3.	Glaucoma
4.	Diabetes Mellitus
5.	Capsule Opacification

Experts

1.	Sebag, J: 11 articles (12/2022 - 03/2016)
2.	Nguyen-Cuu, Jeannie: 5 articles (12/2022 - 01/2018)
3.	Lin, Zhong: 5 articles (01/2020 - 09/2016)
4.	Moonasar, Nived: 5 articles (01/2020 - 09/2016)
5.	Wu, Rong Han: 4 articles (07/2018 - 09/2016)
6.	Nguyen, Justin H: 3 articles (12/2022 - 01/2018)
7.	Sadun, Alfredo A: 3 articles (01/2020 - 01/2019)
8.	Mamou, Jonathan: 2 articles (12/2022 - 11/2019)
9.	Yee, Kenneth M P: 2 articles (12/2022 - 01/2018)
10.	Cheng, Olivia T: 2 articles (11/2021 - 01/2021)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to vitreous floaters:

1.	yttrium-aluminum-garnetIBA 10/01/2023 - "To demonstrate the methodology and efficacy of using scanning laser ophthalmoscopy (SLO) and dynamic optical coherence tomography (OCT) to identify and treat symptomatic vitreous floaters using yttrium-aluminum garnet laser vitreolysis (YLV). " 01/01/2023 - "To assess the long-term efficacy and safety of yttrium-aluminum garnet (YAG) laser vitreolysis for vision degrading myodesopsia (VDM) caused by posterior vitreous detachment (PVD). " 01/01/2020 - "In this interventional and prospective study, 32 eyes of 32 patients with symptomatic vitreous floaters secondary to posterior vitreous detachment (PVD) were treated with a single session of yttrium aluminum garnet (YAG) laser. " 09/23/2022 - "This study aimed to evaluate the long-term safety and efficacy of neodymium-doped yttrium aluminum garnet (Nd:YAG) vitreolysis for symptomatic vitreous floaters as it remains a controversial procedure due to insufficient robust evidence in the literature for the maintenance of the results and absence of adverse effects. " 05/01/2022 - "Visually Disturbing Vitreous Floaters following Neodymium-Doped Yttrium Aluminum Garnet Capsulotomy: A Single-Center Case Series."
2.	Retinaldehyde (Retinal)IBA 01/01/2021 - "196 patients (55 males and 141 females), who were 58.4 (± 9.1) years old, visited a retinal clinic 9.4 (± 9.1) days after they experienced vitreous floaters. " 06/01/2015 - "Vitreous floaters were inconsistently imaged by optical coherence tomography, with only a few patients presenting appreciable condensations close to the retinal surface. " 05/01/2000 - "This method was tested on a patient with a microinfarction of a small retinal arteriole and on two patients with small preretinal parapapillary vitreous floaters. " 10/01/2011 - "[Retinal injury following ND-Yag laser treatment of symptomatic vitreous floaters]." 11/01/2002 - "To the extent that vitreous floaters can multiply and presage the onset of severe retinal injury, the risk of their induction by dermatologic lasers should be minimized. "
3.	NeodymiumIBA 08/01/1993 - "To our knowledge, the use of neodymium YAG laser to treat vitreous floaters has not been previously described. " 08/01/1993 - "Treatment of vitreous floaters with neodymium YAG laser." 09/23/2022 - "This study aimed to evaluate the long-term safety and efficacy of neodymium-doped yttrium aluminum garnet (Nd:YAG) vitreolysis for symptomatic vitreous floaters as it remains a controversial procedure due to insufficient robust evidence in the literature for the maintenance of the results and absence of adverse effects. " 05/01/2022 - "Visually Disturbing Vitreous Floaters following Neodymium-Doped Yttrium Aluminum Garnet Capsulotomy: A Single-Center Case Series." 11/01/2019 - "Neodymium:yttrium-aluminum-garnet (Nd:YAG) laser treatment is performed on vitreous floaters, but studies of structural and functional effects with objective outcome measures are lacking. "
4.	AntioxidantsIBA 12/20/2019 - "Adequate intravitreal antioxidant levels may be protective against vitreous degeneration, possibly preventing and even improving vision degrading myodesopsia as well as mitigating various other vitreo-retinopathies. "
5.	4-hexyloxyaniline (HOA)IBA 02/01/2022 - "Objective visual quality measures including the Strehl ratio (SR), internal spherical aberration (SA), internal comatic aberration (CA), internal high-order aberration (HOA), area ratio of modulation transfer function (MTFa) and Vitreous Floaters Symptom Questionnaire (VFSQ-13) scores were used to compare the efficacy of YAG laser vitreolysis treatment between two groups. "
6.	MicronutrientsIBA 10/04/2021 - "The findings of this study indicate improvements in vision-related quality of life and visual function of patients suffering from vitreous floaters after supplementation with a formulation of antioxidative and antiglycation micronutrients. "
7.	Ranibizumab (Lucentis)FDA Link 10/01/2008 - "The most common adverse ocular reactions reported in patients receiving ranibizumab during clinical trials include conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, and intraocular inflammation. "
8.	microplasminIBA 07/01/2016 - "Various complications after ocriplasmin use were reported by frequency, including mainly vitreous floaters, photopsias, visual acuity decrease, ellipsoid zone changes, subretinal fluid development, enlargement of macular hole, anterior segment changes and electroretinogram alterations. " 09/01/2016 - "Ocular adverse events (OAEs) of ocriplasmin include transient visual loss, intraocular inflammation, vitreous floaters, lens opacification, zonular instability of the lens, and intraocular hemorrhage. " 08/16/2012 - "Ocular adverse events (e.g., vitreous floaters, photopsia, or injection-related eye pain--all self-reported--or conjunctival hemorrhage) occurred in 68.4% of ocriplasmin-injected eyes and in 53.5% of placebo-injected eyes (P<0.001), and the incidence of serious ocular adverse events was similar in the two groups (P=0.26). " 05/01/2022 - "Ocriplasmin-treated participants experienced more short-term visual impairment that was not predictive of final BCVA, as well as vitreous floaters, photopsia, photophobia, eye pain, blurred vision, and dyschromatopsia. "
9.	salicylhydroxamic acid (SHAM)IBA 01/01/2017 - "YAG Laser Vitreolysis vs Sham YAG Vitreolysis for Symptomatic Vitreous Floaters: A Randomized Clinical Trial." 01/01/2006 - "Adverse events reported significantly more often in the pegaptanib group compared with the sham-injection group included vitreous floaters (33% vs 28%, respectively; P < 0.001), vitreous opacities (18% vs 10%; P < 0.001), and anterior-chamber inflammation (14% vs 6%; P = 0.001). " 07/01/2005 - "There was no evidence that pegaptanib 1 or 3 mg was more effective than 0.3 mg. There was no excess of systemic adverse effects with pegaptanib, but ocular adverse effects occurred more commonly with pegaptanib than with sham injection; vitreous floaters (33 versus 8%), vitreous opacities (18 versus 10%) and anterior chamber inflammation (14 versus 6%). "
10.	YttriumIBA 11/01/2018 - "To examine the efficacy and safety of yttrium-aluminium garnet (YAG) laser vitreolysis for the treatment of vitreous floaters. " 11/01/2018 - "Efficacy and safety of yttrium-aluminium garnet (YAG) laser vitreolysis for vitreous floaters." 01/01/2017 - "Neodymium-yttrium-aluminium-garnet (Nd:YAG) laser vitreolysis has been proposed as a treatment modality for symptomatic vitreous floaters. " 01/01/2017 - "Cataracts induced by neodymium-yttrium-aluminium-garnet laser lysis of vitreous floaters."

Therapies and Procedures

1.	Vitrectomy 01/01/2017 - "Visual acuity of most patients remained unchanged or improved following 27-gague pars plana vitrectomy for symptomatic vitreous floaters, resulting in high patient satisfaction. " 04/01/2011 - "Pars plana vitrectomy provides a highly effective treatment for visually disturbing vitreous floaters. " 06/01/2014 - "Approximately 88.8% of patients completed a quality-of-life survey, which revealed that 96% were "satisfied" with the results of the operation, and 94% rated the experience as a "complete success." Sutureless 25-gauge pars plana vitrectomy for symptomatic vitreous floaters improved visual acuity, resulted in a high patient satisfaction quality-of-life survey, and had a low rate of postoperative complications. " 01/01/2019 - "Limited vitrectomy for vision-degrading myodesopsia is clinically effective, in that it improves BCVA, CSF, and patient well-being. " 12/01/2022 - "As MFIOL eyes had 37% improvement in CSF, patients with MFIOL and vision degrading myodesopsia merit consideration of vitrectomy."
2.	Solid-State Lasers 11/01/2018 - "The results of this study conducted in a cohort of 30 Chinese patients showed that YAG laser vitreolysis was a well-tolerated and effective treatment for vitreous floaters. " 10/01/2018 - "Nd:YAG laser vitreolysis using newer technology has been shown safe and effective in treating symptomatic Weiss ring vitreous floaters. " 01/01/2020 - "Safety and Efficacy of YAG Laser Vitreolysis for the Treatment of Vitreous Floaters: An Overview." 01/01/2020 - "YAG laser vitreolysis decreased the amount of vitreous floaters opacities seen on color fundus imaging and improved related symptoms according to the NEI VFQ-25 responses." 05/01/2021 - "This study aims to examine the efficacy and safety in treating vitreous floaters using Nd:YAG laser vitreolysis. "
3.	Lasers (Laser) 01/01/2022 - "This was a single-centre study of adult patients with symptomatic vitreous floaters who underwent laser vitreolysis. " 10/20/2023 - "Vision degrading myodesopsia assessed with optos ultra-widefield scanning laser ophthalmoscope." 09/20/2022 - "Visualization and Grading of Vitreous Floaters Using Dynamic Ultra-Widefield Infrared Confocal Scanning Laser Ophthalmoscopy: A Pilot Study." 01/01/2022 - "LASER VITREOLYSIS IN PATIENTS WITH SYMPTOMATIC VITREOUS FLOATERS." 01/01/2021 - "Acute symptomatic vitreous floaters assessed with ultra-wide field scanning laser ophthalmoscopy and spectral domain optical coherence tomography."
4.	Anesthesia 07/07/2018 - "To compare the safety and efficacy of topical anesthesia versus retrobulbar anesthesia in 27-gauge pars plana vitrectomy (PPV) for vitreous floaters. " 07/07/2018 - "A comparison between topical and retrobulbar anesthesia in 27-gauge vitrectomy for vitreous floaters: a randomized controlled trial." 01/01/2017 - "Topical anesthesia can be considered for 27-guage vitrectomy in patients with symptomatic vitreous floaters." 01/01/2017 - "Three cases of 27-gauge, sutureless pars plana vitrectomy for symptomatic vitreous floaters with topical anesthesia are reported. " 01/01/2017 - "27-Gauge Vitrectomy for Symptomatic Vitreous Floaters with Topical Anesthesia."
5.	Capsulorhexis 11/01/2016 - "To evaluate the safety and efficacy of posterior continuous curvilinear capsulorhexis through the pars plana and 23-gauge vitrectomy in surgical management of dense posterior capsule opacification and vitreous floaters. " 11/01/2016 - "Posterior continuous curvilinear capsulorhexis through the pars plana combined with 23-gauge vitrectomy may be used to remove dense posterior capsule opacification and vitreous floaters in pseudophakic eyes." 11/01/2016 - "Fifteen pseudophakic eyes of 15 patients with dense posterior capsule opacification and vitreous floaters between September 2012 and June 2014 were included; after vitrectomy, posterior continuous curvilinear capsulorhexis through the pars plana was performed. " 11/01/2016 - "SURGICAL REMOVAL OF DENSE POSTERIOR CAPSULE OPACIFICATION AND VITREOUS FLOATERS IN ADULTS BY POSTERIOR CONTINUOUS CURVILINEAR CAPSULORHEXIS THROUGH THE PARS PLANA AND 23-GAUGE VITRECTOMY."